Mutations in the GBA1 gene encoding the lysosomal enzyme glucocerebrosidase (GBA1) are important risk factors for Parkinson's disease (PD). In vitro, altered GBA1 activity promotes alpha-synuclein accumulation whereas elevated levels of alpha-synuclein compromise GBA1 function, thus supporting a pathogenic mechanism in PD. However, the mechanisms by which GBA1 deficiency is linked to increased risk of PD remain elusive, partially because of lack of aged models of GBA1 deficiency. As knocking-out GBA1 in the entire brain induces massive neurodegeneration and early death, we generated a mouse model of GBA1 deficiency amenable to investigate the long-term consequences of compromised GBA1 function in dopaminergic neurons. DAT-Cre and GBA1-floxed mice were bred to obtain selective homozygous disruption of GBA1 in midbrain dopamine neurons (DAT-GBA1-KO). Mice were followed for motor function, neuronal survival, alpha-synuclein phosphorylation and glial activation. Susceptibility to nigral viral vector-mediated overexpression of mutated (A53T) alpha-synuclein was assessed. Despite loss of GBA1 and substrate accumulation, DAT-GBA1-KO mice displayed normal motor performances and preserved dopaminergic neurons despite robust microglial activation in the substantia nigra, without accumulation of endogenous alpha-synuclein with respect to wild-type mice. Lysosomal function was only marginally affected. Screening of microRNAs linked to the regulation of GBA1, alpha-synuclein or neuroinflammation did not reveal significant alterations. Viral-mediated overexpression of A53T-alpha-synuclein yielded similar neurodegeneration in DAT-GBA1-KO mice and † Present address: Diagnostic Development Services, Covance Central Laboratory Services, Geneva, 7 rue Moïse-Marcinhes, 1217, Meyrin, Geneva, Switzerland. 
Introduction
Gaucher's disease (GD), a rare autosomal recessive disease primarily affecting the mononuclear phagocyte system, is the most common lysosomal storage disorder. GD is linked to loss of function mutations in the gene encoding the lysosomal hydrolase beta-glucocerebrosidase (GBA1), an enzyme that catalyses the breakdown of glucosylceramide (GlcCer) and glucosylsphingosine, rendering this molecule vital for sphingolipid degradation and lysosomal metabolism. Although homozygous mutations in GBA1 are linked to GD, heterozygous mutations of this gene are found in 5-10% of Parkinson's disease (PD) and dementia with Lewy body (DLB) patients (1, 2) , making GBA1 mutations the most common genetic risk factor for these disorders (3, 4) . The identification of Lewy bodies (LB) in the brain of GD patients (5) and the discovery that beta-glucocerebrosidase may occasionally be a component of these proteinaceous aggregates (6) further suggested a link between GD and PD. Furthermore, Lewy body pathology might be more extensive in GBA1 mutant brains (7) , but this is not universally found (8) . However, most GBA1 mutation carriers will never develop PD or DLB despite diminished glucocerebrosidase (GCase) activity. Likewise, the mechanism by which GBA1 deficiency is linked to increased risk of PD remains unknown.
In contrast, several studies suggest an association between GBA1 deficiency and alpha-synuclein (a-syn) processing (9) (10) (11) . Expression of mutant GBA1 or knock-down of wild-type GBA1 in vitro leads to amyloid formation of purified a-syn. This process is thought to be dependent upon the GBA1 substrate GlcCer, whose concentration is augmented in GBA1-deficient cells, by stabilizing the soluble oligomeric intermediates of a-syn. Conversely, increased levels of a-syn disrupt the intracellular trafficking of GBA, thus resulting in decreased GBA1 levels and activity in lysosomes (10) . However, data from PD patients with GBA1 mutations (PD þ GBA) show that there is no accumulation of GlcCer in the brain of PD þ GBA1 patients (12) . Furthermore, GBA1 activity has been reported to be decreased in the substantia nigra of PD þ GBA1 brains (13) . It should be noted that a recent study using blood samples from a large cohort of PD and PD þ GBA1 patients suggests that GBA1-decreased activity is associated with PD independently from the GBA1 mutations (14) .
There is no experimental in vivo mammalian model available to directly address the role of GBA-linked lysosomal deficiency as an etiological component in PD or related synucleinopathies. Knocking out the GBA1 gene (15) results in perinatal death due to compromised epidermal permeability (16) . Moreover, animals where conditional deletion is restricted only to the central nervous system die within 3 weeks after birth (17) , rendering them poorly amenable for studying the role of GBA1 in an age-related disorder such as PD. Here, we developed a mouse model of targeted inactivation of GBA1 in dopaminergic neurons (DAT-GBA1-KO) to investigate the long-term consequences of compromised GBA1 function on motor function, neuronal survival, a-syn phosphorylation and glial activation, in aged animals and upon nigral viral vector-mediated mutated (A53T) a-syn overexpression. Our results show that dopaminergic GBA1-deficient mice have no significant difference in motor behaviour, nigral neurodegeneration and a-syn pathology with respect to wildtype (WT) mice. However, increased microglial activation was observed in DAT-GBA1-KO midbrain compared with controls, which implies a link between neuronal GBA1 loss and the inflammatory process independent of neuronal death.
Results
Conditional ablation of GBA1 activity in the substantia nigra of DAT-GBA1-KO mice
To selectively disrupt GBA1 function in dopaminergic neurons, we crossed animals heterozygously expressing Cre driven by the dopamine transporter promoter (DAT-Cre) with GBA1-floxed animals, resulting in DAT-Creþ/À; GBA1 Floxþ/þ (DAT-GBA1-KO; Fig. 1A ). Contrary to reports of premature death in pan neuronal GBA1-KO animals (17), DAT-GBA1-KO mice displayed a healthy phenotype and were able to age up to 20 months.
As there are no suitable antibodies to detect the mouse GBA1 protein by immunohistochemistry, we employed a modification of the in situ zymology method described by Takagi et al. (18) to assess the level of GBA1 activity in the SNc. This method takes advantage of the GBA1-mediated conversion of 4-methlylumbelliferyl-D-glucopyranoside (4-MUG) into the fluorescent product 4-methylumbelliferone (4-MU). DAT-GBA1-KO mice displayed diminished 4-MU fluorescence in the SNc compared with WT littermates (Fig. 1B) . To confirm the anatomical localization, we subsequently labelled the tissue for tyrosine hydroxylase (TH) immunofluorescence (Fig. 1B) , detecting co-localization of the TH staining within the area of disrupted GBA1 activity. No fluorescence was observed when conduritol-B-epoxide (CBE), a GBA1 inhibitor, was added to the buffer (Fig. 1C) . Assessment of GBA1 activity in ventral midbrain homogenates revealed 40% reduction in DAT-GBA1-KO compared with WT ( Fig. 1D) , which is comparable to the 50% GBA1 activity decrease previously reported after excision of exons 9-11 in GBA1-floxed mice crossed with Cre heterozygotes (19) . Such only partial reduction of GBA1 activity on brain homogenates is due to the preserved expression of GBA1 in non-neuronal cells. Consistent with the loss of GBA1 function in DAT-GBA1-KO mice, immunohistochemical detection of the GlcCer revealed prominent substrate accumulation in the substantia nigra of DAT-GBA1-KO mice (Fig. 1E ).
We next determined the level of lysosomal membrane permeabilization (LMP) by analysing the cytosolic activities of the lysosomal enzymes b-hexosaminidase, acid phosphatase and cathepsin D in subcellular fractions of ventral midbrain homogenates obtained from mice at different ages (young: 4-5 months, middle-aged: 14-15 months and old: 20-22 months). Consistent with an age-related increase in LMP, the cytosolic activities of the three enzymes were higher in old compared with young mice (Supplementary Material, Fig. S1 ). For b-hexosaminidase, two-way ANOVA revealed an effect of age (F (2, 12) ¼ 16.75, P < 0.001), with significantly increased cytosolic activity in old mice compared with young mice regardless of genotype, as well as in old compared with middle-aged DAT-GBA1-KO. Regarding cytosolic acid phosphatase activity, there was an effect of genotype (F (1, 12) ¼ 37.82, P < 0.0001), age (F (2, 12) ¼ 1722, P < 0.0001) and a genotype Â age interaction (F (2, 12) ¼ 65.94, P < 0.0001). Increased cytosolic activity occurred in aged compared with middle-aged (P < 0.0001) and with young mice (P < 0.0001) regardless of genotype. In addition, DAT-GBA1-KO displayed significantly decreased cytosolic acid phosphatase activity compared with their WT littermates at middle age (P < 0.05) and increased activity (P < 0.0001) in aged mice.
Altogether, these results demonstrate a diminished GBA1 activity and GlcCer accumulation in the SNc with mild (though significant) consequences on LMP, supporting the claim that GBA1 was knocked down in the dopamine neurons.
Nigral GBA1 impairment does not lead to motor dysfunction nor dopaminergic neurodegeneration in aged mice As GBA1 mutations have been associated with parkinsonism (20) , we sought to evaluate motor performance in DAT-GBA1-KO mice. To this end, we tested aged (20-22 months) DAT-GBA1-KO and WT mice of both genders in the pole test and challenging beam. There was no significant difference either in T-Turn or T-total between the two groups in the pole test ( Fig. 2A) , as well as in the challenging beam (Fig. 2B) . We observed similar results in young and middle-aged mice (data not shown). Accordingly, DAT-GBA1-KO mice showed no difference in the number of TH-positive neurons or total number of Nissl-stained neurons in the SNc, when compared with WT mice (Fig. 2C) . These results indicate that dopaminergic GBA1 deficiency is not sufficient to induce dopamine neuron loss in the SNc of mice and has no impact on motor behaviour.
As GBA1 deficiency has also been linked to a-syn accumulation in vitro (9,10), we next assessed a-syn and phosphorylated a-syn in the SNc. Histological analysis showed no increase in asyn expression in the SNc of DAT-GBA1-KO mice with respect to WT (Fig. 2D) . Comparably, we found no labelling for phosphorylated a-syn in these brains (Fig. 2D, inset) , indicating that dopaminergic GBA1 deficiency does not lead to altered a-syn expression or processing in vivo.
DAT-GBA1-KO mice show increased microglial activation in the substantia nigra Nigral GBA1 deficiency does not appear be sufficient to induce a parkinsonian phenotype or dopaminergic loss in aged mice. Nevertheless, elevated levels of glycolipids, such as GBA1 substrates, can induce microglial activation (21, 22) . We next evaluated the extent of glial activation in the SN of DAT-GBA1-KO mice. Both genotypes displayed similar levels of GFAP (Fig. 3A) , suggesting no detectable activation of astrocytes in DAT-GBA1-KO mice. However, levels of the microglial marker Iba1 were significantly increased in the SN of DAT-GBA1-KO mice compared with WT ( Fig. 3A) , indicating a higher level of microglial activation in mutant mice.
To confirm these findings, we next analysed microglial activation in detail by fractal analysis, a method that accurately depicts subtle changes in microglial morphology (23) . To this end, we isolated microglial cells from binarized images of Iba1/DAB-stained SN sections, and we calculated individual values for classical shape descriptors (form factor, convexity, solidity). Outlined binary images were then used to calculate box-counting fractal dimension (D b ), a quantitative parameter that provides a statistical index of complexity, hence it is indicative of the degree of ramification of a microglial cell and inversely proportional to its degree of activation (Fig. 3B ). Fractal dimension of SN microglia was significantly decreased in DAT-GBA1-KO aged mice compared with WT, suggesting increased microglial activation in the SN of mutant mice (Fig. 3C ). Form factor was increased in DAT-GBA1-KO, indicating a more rounded shape in microglia from DAT-GBA1-KO mice compared with WT cells (Fig. 3C ). Convexity, a shape feature reported to be inversely correlated to microglial fractal dimension (24, 25) , was similarly higher (Fig. 3C) . Finally, solidity did not show a significant difference between the two sets of cells, indicating no disparity in their spatial density (Fig. 3C) . These results indicate a chronic activation of microglia in the SN in response to dopaminergic GBA1 deficiency, and they are consistent with reports of wild-type microglial activation in response to GBA1-mutant neurons (17, 26, 27) .
Nigral GBA1 deficiency has no effect on the vulnerability of dopaminergic neurons to a-syn-induced neurodegeneration
To test the hypothesis that GBA1 deficiency may increase dopaminergic neuronal vulnerability, WT and DAT-GBA1-KO received a unilateral injection of AAV expressing human A53T a-syn (Fig. 4) . Both control and mutant mice displayed a significant loss of TH-positive neurons (F (1, 12) ¼ 80.53, P < 0.0001) confirmed with counts of Nissl stained neurons (F (1,12) ¼ 43.5, P < 0.0001), together with marked human-a-syn (F (1, 12) ¼ 700.6, P < 0.0001) and phospho-S129-a-syn (F (1, 12) ¼ 46.48, P < 0.0001) staining on the injected side ( Fig. 4A and C). Genotype did not impact the extent of a-syn-induced neurodegeneration (Fig. 4B ) or the extent of human-a-syn levels and phosphorylation status (Fig. 4C ). These data suggest that dopaminergic neurons vulnerability to a-syn overexpression is not related to impairment of GCase activity, at least upon GBA1 disruption in dopaminergic neurons of the substantia nigra.
To evaluate the potential contribution of GBA1 deficiency to inflammation in the context of a-syn-induced neurodegeneration, we next evaluated GFAP and Iba1 expression in the SN of AAV-injected mice (Fig. 5A) . Ipsilateral side displayed an increase of GFAP staining, corresponding to expected astrocyte proliferation, but there was no effect of genotype (Fig. 5B ). Iba1 staining, on the contrary, was increased in the ipsilateral SN of WT mice but unchanged in DAT-GBA1-KO mice, when compared with respective contralateral sides. However, this can be explained by basal (contralateral) levels of microglial activation, which were significantly higher in GBA1-deficient mice compared with control (Fig. 5B) . It is worth noting the higher level of Iba-1 staining in aged WT animals (18%, see Fig. 3A ) compared with younger 6-month-old mice (12%, Fig. 5B ), which might be due to basal microglial activation being increased in aging (28, 29) . Microglial morphology analysis also indicated increased activation not only in AAV-injected mice but also in contralateral SN of DAT-GBA1-KO (Fig. 5C ). Fractal dimension and shape descriptors quantification revealed decreased activation in the contralateral SN of WT mice compared with the other three groups (Fig. 5D) . Altogether, these results are consistent with our previous observations in aged DAT-GBA1-KO mice, (see Fig. 3 ), and suggest a link between dopaminergic GBA1 deficiency and microglial activation, however without consequences upon the susceptibility of dopamine neuron towards a-syn overexpression.
miRNAs related to GBA1 expression and activity are not differentially regulated in DAT-GBA1-KO mice
To determine whether nigral GBA1 deficiency may lead to dysregulated miRNA expression profiles in DA neurons, we assessed the expression of miRNAs selected on the basis of either their reported ability to modulate GCase activity (30) (Supplementary Material, Fig. S2A ) or their predicted targeting of GBA1 according to TargetScan (31) (Supplementary Material,  Fig. S2B ). None of the 12 miRNAs investigated was differentially expressed between DAT-GBA1-KO and WT mice.
Discussion
In the past decade, several genetic studies have associated GBA1 mutations with increased risk of PD. However, the relative contribution of altered GBA1 activity to the pathogenesis of the disease remains controversial (32) . Our incomplete understanding of the relationships between GBA1 impairment and PD, potentially via a-syn toxicity, is due to lack of suitable animal models. A number of attempts at developing a GD model have been undertaken. Reduced GBA1 enzymatic activity and its effects have been investigated after pharmacological inhibition with the GBA1 inhibitor CBE (33, 34) and in GBA1 mutant models in mouse and fly (9, 35, 36) , leading to insights on the mechanisms of protein aggregation and lysosomal dysfunction. However, full GBA1 knock-out mice are not viable (15, 16) , and those where GCase deficiency is limited to the CNS display a rapid onset and extreme severity of the disease (17) , leaving only the possibility of studies in very young animals. Here we report the generation of a mouse line with selective GBA1 deficiency in dopaminergic neurons, using the Cre recombinase system driven by the DAT promoter in GBA1-floxed animals (DAT-GBA1-KO mice). These animals are able to age, but exhibit neither motor disorder nor dopaminergic neurodegeneration and no increased susceptibility to a-syn induced neuronal death. On the contrary, DAT-GBA1-KO mice display an elevated basal inflammation in the SN, with increased microglial activation as measured by Iba1 staining and morphological analyses. Screening of miRNAs linked to the regulation of GBA1, a-syn or neuroinflammation did not reveal any significant alterations in DAT-GBA1-KO mice, suggesting that miRNA-related adaptive mechanisms do not operate following loss of GBA1 in dopaminergic neurons in this model. It should be noted that the 40% reduction of GBA1 activity in the ventral midbrain observed in our model is comparable to the 58% decrease found in the SN of PD-GBA1 patients (13), but given that our model is DAT-positive neuron-specific, GBA1 activity in our brain homogenates might be diluted with enzymatic activity from glial cells. Inflammation has been previously reported in genetic and pharmacological models of GBA1 deficiency. L444P and R463C mutations, as well as systemic inhibition of GBA1 with CBE are associated with microglial activation in mice (33, 34) . Moreover, microglia has been identified as responsible for the neuronal death observed in Nestin-Cre/GBA-Flox mice, a model of neuronopathic GD with GBA1-deficient neurons, astrocytes and oligodendrocytes but fully functional microglia (26) . These mice also displayed an increase in astroglial and microglial cathepsin D in areas where neurodegeneration and gliosis were observed (37) . Contrary to Nestin-Cre/GBA1-Flox mice, DAT-GBA1-KO mice have normal microglia and astroglia, as the GBA1 impairment is limited to dopaminergic neurons. We hypothesize that microglial activation observed in DAT-GBA1-KO mice might be due to lysosomal impairment in SN neurons. Even though, we observed a modest LMP in the ventral midbrain of DAT-GBA1-KO mice, this remains insufficient to trigger neuronal apoptosis but possibly sufficient to generate stress signals. These dangerassociated molecular patterns (DAMPs) released from damaged but not necessarily dying neurons have been suggested as a major source of neuroinflammation in lysosomal storage disorders (38) . Microglial activation by glycosphingolipids (such as glucocerebrosides) has been described in an extreme inflammatory situation where limited neuronal loss is observed, such as experimental autoimmune encephalomyelitis (21) . Regardless of neuronal apoptosis, inflammation in lysosomal storage disorders may be further amplified by engulfed sphingolipids, which can activate microglia either directly (39) or indirectly via astrocytes (21) . Furthermore, GlcCer accumulation can impair neuronal Ca 2þ homeostasis (40) , which in turn induces DAMP release (41) . In our model, microglia might be sensing a modest but existent lysosomal impairment in dopaminergic neurons, and therefore being chronically activated in the SN. Early and severe microglial activation in the SN has also been described in a neuronopathic model of GD (27) , where it has been associated with its rapid neuronal loss. GBA1 selective impairment is not sufficient to induce dopaminergic neuronal death in DAT-GBA1-KO mice, although a key difference between the well-established Nestin-Cre/GBA1-flox model and our DATCre/GBA1-flox mice is the lack of GBA deficiency in astrocytes. Recently, astrocytic lysosomal impairment and ensuing deficits in astrocyte autophagy have been shown to be sufficient to trigger neurodegeneration (42) , implying that astrocytes may play a key role in the neurodegenerative process that takes place in lysosomal storage disorders. Not only DAT-GBA1-KO astrocytes retain normal GBA1 activity, but also neither astrogliosis nor increase in GFAP expression has been observed in these mice, and could be related to the lack of dopaminergic cell loss observed in this model. The lack of dopaminergic neurodegeneration despite loss of GBA1 activity and GlcCer accumulation also suggests that compensatory mechanisms involving nondopaminergic neurons and/or non-neuronal cells may take place. These may include a release of GBA1 via lysosomal exocytosis from WT cells as well as the secretion of some of the excess GlcCer by GBA1 KO neurons. Furthermore, inflammation-induced neurodegeneration is not observed in this model. Systemic LPS mouse models with massive inflammation have been reported to cause neuronal loss (43) . Our study however shows a moderate and localized inflammation in the SN that may not be sufficient per se to induce the loss of dopaminergic neurons.
The pathological hallmark in PD is the presence of LB, which contain a-syn and other components. As several reports have related a-syn with GBA1 function, targeting the GBA1-lysosomal pathway has been proposed as an interesting strategy for the treatment of PD (44, 45) . A mechanistic link between GBA1 deficiency and a-syn aggregation was proposed following the in vitro demonstration that reduced GBA1 function induces lysosomal dysfunction, a-syn accumulation and that the GlcCer promotes the stabilization of oligomeric forms of a-syn (10) . This attractive hypothesis remains to be replicated in vivo, or in a more integral preparation where other neuronal cell types are present. Indeed, reports from human patients and experimental models are controversial on this subject and both a loss of function and a toxic gain of function may underlie the association between PD and GBA1. Furthermore, despite decreased GCase activity in PD brains (13, 46) there is no substrate accumulation in brain homogenate of PD patients with GBA1 mutations (12) . It remains possible however that neuronal levels of substrate could be specifically increased. In mice, pharmacological inhibition of GBA1 with CBE leads to a-syn accumulation (33, 34, 47) . Another report found that disease-associated GBA1 point mutations increase a-syn levels but without relationship with GCase activity (9) , whereas recent studies show that increasing GBA activity helps decreasing phosphorylated and proteinase-K resistant a-syn levels in mice overexpressing a-syn (48, 49) . Thus, animal models with PD-associated GBA1 mutations where GBA1 activity is moderately decreased might be more relevant to study lysosome and endoplasmic-reticulum dysfunctions associated with protein misfolding and aggregation. A recent report on GBA1-deficient zebrafish (a species lacking a-syn) showed early microglial activation and increased levels of miR-155, prior to a-syn-independent neuronal death (50), which suggests that GBA1 deficiency might be directly related to inflammation and degeneration independently of a-syn. If our results indicate a negligible effect of GBA1 loss of function when restricted to dopaminergic neurons, our study also points to a possible non-cell autonomous effect of GBA deletion in dopaminergic neurons and suggests an association between GBA1 and neuroinflammation independent of both a-syn and neuronal death. Accordingly, non-neuronal cell types may play a key role in the PD-GBA1 link in vivo, a process that now deserves further experiments for elucidating this link.
Materials and Methods

Generation of DAT-GBA1-KO mice
Heterozygous mice expressing Cre recombinase under the control of the dopamine transporter promoter [DAT-Cre (51)] were bred with mice where the GBA1 gene is flanked by loxP sites between exons 9 and 11 [GBA1-Flox (19) ] to obtain animals with a selective homozygous disruption of GBA1 in midbrain dopamine neurons (DAT-Creþ/À; GBA1 floxþ/þ, referred hereafter as DAT-GBA1-KO) whereas DAT-CreÀ/À; GBA1 floxþ/þ mice were used as wild-type littermate controls (referred hereafter as WT). All experiments were performed in accordance with the European Community Council Directive (2010/63/EU) on the protection of animals used for scientific purposes. The Institutional Animal Care and Use Committee of Bordeaux (CE50) approved experiments under license number 5012099-A.
In situ zymology
Eighteen-month-old DAT-GBA1-KO and WT mice were terminated and brains were collected, snapfrozen, sectioned (20 lm thickness) at À15 C in a cryostat and mounted onto superfrost slides. Sections were incubated in McIlvaine buffer pH 5.6 with or without 4-MUG (5 mM) in the presence of sodium taurodeoxycholate (22 mM). Additional sections were incubated with CBE (10 mM) to specifically inhibit GBA1 activity. After 1 h at 37 C, enzymatic reaction was stopped with a solution of glycine (0.25 M, pH 10). Slices were then immediately imaged in a Zeiss Axio Imager-M2 fluorescence microscope equipped with an ORCA-R2 camera (Hamamatsu), using the DAPI filter and the 40Â objective (0.75 NA). Exposure time was the same for all pictures. Position (x,y) of the microscope-motorized stage was recorded using the MorphoStrider software (ExploraNova) and used later to re-image the exact same field of view after TH immunohistochemistry. To determine colocalization with dopaminergic neurons, immediately after 4-MUG imaging, sections were fixed for 30 min in 4% paraformaldehyde (PFA) and incubated overnight at 4 C with a rabbit anti-TH polyclonal antibody (1:2000, ab6211, Abcam). Sections were washed and subsequently labelled with secondary goat anti-rabbit IgG conjugated with Alexa FluorV R 488 (1:500; Thermo Fisher), mounted with ProLongV R (Thermo Fisher) mounting media and imaged the day after.
GCase activity and LMP assays LMP assays were performed from cytosolic and lysosomal fractions from ventral midbrain isolated as previously described (52) and three lysosomal enzymatic activities were detected in both fractions. ACP2/acid phosphatase and cathepsin D activities were determined with the Acid Phosphatase Assay Kit from Sigma (CS0740) and the Cathepsin D Activity Assay Kit from Abcam (ab65302), respectively, according to the manufacturer's instructions. b-hexosaminidase activity was measured as described (53) . Briefly, pre-warmed (37 C) substrate (8 mM 4-methyllumbelliferyl-N-acetyl-B-D-glucopyranoside) solution and sample (cytosolic or lysosomal fractions) were mixed in a 96-well plate and incubated at 37 C for 30 min. The reaction was stopped by adding stop solution (2 M glycine, 2 M Na2CO3) and absorption was measured at 405 nm. LMP is expressed as the percentage of activity detected in cytosol fraction compared with total enzymatic activity which corresponds to activity from lysosomal and cytosol fraction together
Behavioural assessment
Motor coordination and balance were assessed with the traversing beam task (54) . Briefly, 18-month-old mice were trained on three consecutive days to traverse a beam made of four narrowing Plexiglas segments. On the day of the test, a mesh grid (1 cm 2 ) of corresponding width was placed over each segment of the beam, leaving a 1 cm space between the grid and the beam surface. Animals were videotaped while traversing the grid-surfaced beam for a total of five trials. Videotapes were blindly rated for number of errors (sideslips) and time to traverse the beam.
The pole test protocol was performed as previously described (55, 56) . Briefly, mice were placed head upward on the top of a vertical wooden rough-surfaced pole (diameter 1 cm, height 50 cm). Mice were habituated to the pole on the day prior testing, then allowed to descend five times. The total time until the mouse reached the floor was recorded (T-total) as well as the time needed for the mouse to turn downward (T-turn). For each session of five trials, the best performances were kept for T-turn and T-total values.
Viral vector-mediated a-syn overexpression
Six-month-old mice were unilaterally injected in the SNc by stereotaxic surgery (coordinates from bregma anteroposterior: À2.9; lateral: þ1.3; dorsoventral: À4.5) with 120 nl of AAV2/9 (7.0 Â 10 12 vg/ml) expressing human A53T a-syn under the control of the synapsin I promoter as previously described (57) . Recombinant vector production is described in detail elsewhere (57) . Following electrophysiological recordings of dopaminergic neurons to ensure correct anatomical location of injection site, AAV2/9 were injected with a glass pipette at 0.4 ml/min and the pipette was left in place for 5 min after injection to avoid leakage. Animals were sacrificed 12 weeks after surgery.
Histopathological analysis
Mice were anaesthetized with pentobarbital (100 mg/kg ip) and intracardially perfused with 0.9% saline followed by ice cold 4% PFA in 0.1 M PB. Brains were post-fixed for 3 h in 4% PFA, then cryoprotected in 20% sucrose in 0.1 M PBS, frozen in isopentane at À70 C and stored at À80 C. The 40 lm free-floating coronal sections were collected for immunohistochemistry and incubated overnight with primary antibodies (see Table 1 ). The staining was revealed using anti-mouse or anti-rabbit HRP EnVisionV R kit (Dako) for 30 min followed by DAB staining. For substantia nigra pars compacta (SNc) cell counts, every fourth section was processed for TH immunohistochemistry and counterstained with cresyl violet, resulting in six sections to be counted per animal. Stereology was performed using the Mercator Pro software (Explora Nova) coupled to a Leica DM-6000B microscope with a motorized XYZ stage. The number of neurons in the SNc was estimated using the optical fractionator method and calculated based on the following formula: N ¼ RQ-Â 1/ssf Â 1/asf Â t/h, where N is the estimate of the total number of cells, RQ-is the number of objects counted, ssf is the section sampling fraction, asf is the area sampling fraction, and t/h is the actual section thickness divide by the height of the dissector.
a-syn, pS219-a-syn, GFAP and Iba1 expression were quantified on high-resolution images of midbrain sections obtained in a Nanozoomer 2.0 HT slide scanner (Hamamatsu). Briefly, images were opened in the software ImageJ (NIH), and the area of staining was calculated by automatic thresholding, after delineation of the structure of interest. The thresholded area was then compared with the whole delineated region to obtain the percentage of staining. Two sections, representing different coronal levels of the SN, were quantified for each animal.
To assess GlcCer accumulation in the SNc by immunofluorescence, sections were incubated overnight in primary antibodies against GlcCer and TH (see Table 1 ). Sections were washed and subsequently labelled with corresponding secondary IgGs conjugated with Alexa FluorV R 488 or 568 (1:500; Thermo Fisher), mounted and imaged the day after in a Zeiss Axio Imager-M2 fluorescence microscope.
Microglial morphology
High-resolution z-stack images (z-step: 2 mm) of Iba1-stained midbrain sections obtained in a Nanozoomer 2.0 HT slide scanner were opened in ImageJ, processed for image segmentation and fractal analysis by a semi-automated method. Briefly, zstacks were converted to maximal projection images with the stack 'sum' function. Then, a region occupied by one microglial cell and its processes (but not processes from other cells) was delineated with the freehand tool and an automatic local threshold (Otsu) was applied. Overlapping and out-of-focus cells were discarded. The resulting binary image was exported to the FracLac plugin (58) . Area and perimeter of cells and their convex hulls were measured with ImageJ default tools to calculate shape descriptors. Fractal box counting dimension, form factor (4p Â cell area/cell perimeter 2 ), convexity (convex hull perimeter/cell perimeter) and solidity (cell area/convex hull area) were calculated for at least 20 cells per animal.
mRNA extraction and qRT-PCR
Total RNA from the ventral mesencephalon was purified with the miRNeasy Micro Kit (QIAGEN) according to the manufacturer's instructions. cDNA was synthesized using miScript II RT Kit (QIAGEN). PCR amplification and quantification were performed on a LightCycler LC480 II (Roche). Primers were tested by qRT-PCR and gel electrophoresis for the absence of primerdimer artefacts and multiple products. Triplicate qRT-PCR reactions were done twice for each sample, using transcript-specific primers (600 nM) and cDNA (10 ng) in a final volume of 10 ml. The SYBR Premix Ex Taq II (Takara) was used according to manufacturer's instructions. The Ct value of each microRNA was normalized against that of U6. The relative level of expression was calculated using the comparative (2 ÀDDCt ) method (59).
miRNAs were selected based on their reported ability to modulate GCase activity (30) , to regulate a-syn-induced neuroinflammation (60) or on the prediction to target mouse GBA1 according to TargetScan (31) . Primer sequences: miR-9-5p: GTCTTT GGTTATCTAGCTGTATGA; miR-22-3p: GCTGCCAGTTGAAG AACTGT; miR-217-5p: TGCATCAGGAACTGACTGGA; miR-205-5p: CTTCATTCCACCGGAGTCTG; miR-140-3p: CCACAGGGTA GAACCACGG; miR-142: GCTCCATAAAGTAGGAAACACT; miR-127-5p: CTGAAGCTCAGAGGGCTCTGAT; miR-127-3p: GATCC GTCTGAGCTTGGCT; miR-155: GTTAATGCTAATTGTGATAGGG GT; let 7b: CTA-TAC-AAC-CTA-CTG-CCT-TCC-C; miR-16-5p: TAG-CAG-CAC-GTA-AAT-ATT-GGC-G; miR-195-5p: GTA-GCA-GCA-CAG-AAA-TAT-TGG-C; U6 forward: GGAACGATACAGAGA AGATTAGC. U6 reverse: AAATATGGAACGCTTCACGA.
Statistical analysis
Histopathology data from aged mice were analysed by unpaired t-tests. In data from AAV-injected mice and GCase activity, groups were compared by two-way ANOVA with genotype and treatment as independent variables, followed by Tukey's multiple comparison tests. For LMP assays and behaviour, groups were compared by two-way ANOVA with genotype and age as independent variables, followed by Tukey's multiple comparison tests. Statistical analyses were performed in GraphPad Prism 6 software. For all statistical tests, the level of significance was set at P < 0.05 (significant P-values are indicated in figure legends). All data are expressed as mean 6 SEM unless indicated otherwise. 
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